Interleukin-2 therapy of human cancer: potential benefits versus toxicity.

No abstract is available for this paper.

• Publication year

  1989

• Venue

  Journal of Clinical Oncology

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1200/JCO.1989.7.1.1PMID 2783337
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Production of multiple cytokines by clones of human large granular lymphocytes

  2004cited by this paper
• Cardiorespiratory effects of immunotherapy with interleukin-2.

  1989cited by this paper
• Effectiveness and tolerability of low-dose cyclophosphamide and low-dose intravenous interleukin-2 in disseminated melanoma [corrected].

  1988cited by this paper
• Lymphokine-activated killer cells in rats. III. A simple method for the purification of large granular lymphocytes and their rapid expansion and conversion into lymphokine-activated killer cells

  1988cited by this paper
• A phase I study of recombinant interleukin 2 plus recombinant beta-interferon.

  1988cited by this paper
• The in vitro function of lymphocytes from 25 cancer patients receiving four to seven consecutive days of recombinant IL-2.

  1988cited by this paper
• Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer.

  1987cited by this paper
• Successful treatment of advanced murine renal cell cancer by bicompartmental adoptive chemoimmunotherapy.

  1987cited by this paper
• Immunotherapy of advanced cancer.

  1987cited by this paper
• Recombinant interleukin 2 toxicity, pharmacokinetics, and immunomodulatory effects in a phase I trial.

  1987cited by this paper
• Lymphokine-activated killer cell activity Characteristics of effector cells and their progenitors in blood and spleen.

  1987cited by this paper
• Effect of corticosteroid on the antitumor activity of lymphokine-activated killer cells and interleukin 2 in mice.

  1986cited by this paper
• Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin 2.

  1986cited by this paper
• Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer.

  1985cited by this paper
• Direct evidence for the role of LGL in the inhibition of experimental tumor metastases.

  1985cited by this paper
• Adoptive immunotherapy of established pulmonary metastases with LAK cells and recombinant interleukin-2.

  1984cited by this paper

• Genetically Modified Murine Adipose-Derived Mesenchymal Stem Cells Producing Interleukin-2 Favor B16F10 Melanoma Cell Proliferation

  2015cites this paper
• This information is current as T Cells + and CD 8 + Human CD 4 IL-2 Upregulates CD 86 Expression on

  2012cites this paper
• Clinical Results and Characterization of Tumor-infiltrating Lymphocytes with or without Recombinant Interleukin 2 in Human Metastatic Renal Cell Carcinoma 1

  2006cites this paper
• Rationale for immunotherapy of renal cell carcinoma

  2004cites this paper
• Herpes Simplex Virus (HSV)-Mediated ICAM-1 Gene Transfer Abrogates Tumorigenicity and Induces Anti-Tumor Immunity

  1999cites this paper
• In vivo interleukin-2 gene therapy of established tumors with herpes simplex amplicon vectors

  1999cites this paper
• Granulocyte–macrophage colony-stimulating factor-associated histiocytosis and capillary-leak syndrome following autologous bone marrow transplantation: two case reports and a review of the literature

  1998cites this paper
• PULMONARY COMPLICATIONS OF CANCER THERAPY

  1998cites this paper
• [Radiation- and chemically-induced respiratory manifestations].

  1997cites this paper
• Immunopharmacology and Immunotherapy of Human Cancer

  1996cites this paper
• Vessel wall modification in venous pathology. Application to the study of phlebotonic drugs.

  1996cites this paper
• Cyclophosphamide plus tumor necrosis factor‐α chemoimmunotherapy cured mice: Life‐long immunity and rejection of re‐implanted primary lymphoma

  1995cites this paper
• Adjuvant Chemoimmunotherapy for Hepatocellular Carcinoma Patients: Adriamycin, Interleukin‐2, and Lymphokine‐Activated Killer Cells Versus

  1995cites this paper
• Autologous bone marrow transplantation.

  1995cites this paper
• [Generation and activation of tumor-infiltrating lymphocytes (TIL) within the scope of lymphokine activated killer cell therapy (LAK-TIL therapy) in patients with advanced breast and ovarian carcinoma].

  1995cites this paper
• Preoperative factors of prognostic significance in gastric cancer.

  1995cites this paper
• Addition of interleukin 12 to low dose interleukin 2 treatment improves antitumor efficacy in vivo.

  1995cites this paper
• Intrapleural administration of interleukin 2 in pleural mesothelioma: a phase I-II study.

  1995cites this paper
• The immunobiological effects of interleukin-2 in vivo

  1994cites this paper
• Phase I study of interleukin-2 combined with interferon-alpha and 5-fluorouracil in patients with metastatic renal cell cancer.

  1994cites this paper
• Adoptive cellular therapy of urological neoplastic disease.

  1994cites this paper
• Recombinant interleukin-2 in cancer: basic and clinical aspects.

  1994cites this paper
• Phase I Study of Interleukin-2 Combined with Interferon-α and 5-Fluorouracil in Patients with Metastatic Renal Cell Cancer

  1994cites this paper
• Interferon-α Primed Tumor-Infiltrating Lymphocytes Combined with Interleukin-2 and Interferon-α as Therapy for Metastatic Renal Cell Carcinoma

  1993cites this paper
• Interleukin 2 therapy: current role in surgical oncological practice

  1993cites this paper
• Autologous Tumor-Cell Vaccination and Lymphokine-Activated Tumor-Infiltrating Lymphocytes (LAK-TIL)

  1993cites this paper
• Symposium on health effects of gasoline: panel discussion on evaluation of the suitability of the existing exposure data for risk characterization.

  1993cites this paper
• Cytokine modulation of the susceptibility of acute T-lymphoblastic leukemia cell lines to LAK activity.

  1993cites this paper
• Postoperative chemoimmunotherapy for the treatment of liver cancer.

  1993cites this paper
• Clinical results and immunologic effects of a mixed bacterial vaccine in cancer patients

  1993cites this paper
• Psychoneuroimmunological issues in psycho-oncology.

  1993cites this paper
• The pharmaceutics and delivery of therapeutic polypeptides and proteins

  1993cites this paper
• Interferon-alpha primed tumor-infiltrating lymphocytes combined with interleukin-2 and interferon-alpha as therapy for metastatic renal cell carcinoma.

  1993cites this paper
• Pulmonary toxicity of antineoplastic therapy.

  1992cites this paper
• Cancer immunotherapy: are the results discouraging? Can they be improved?

  1992cites this paper
• Susceptibility of acute myelogenous leukemia blasts to lysis by lymphokine-activated killer (LAK) cells and its clinical relevance.

  1992cites this paper
• Bioavailability of interleukin-2 after reconstitution with albumin.

  1992cites this paper
• In vitro development of lymphocytes that function as progenitors for mucus‐secreting lymphokine‐activated killer (LAK) cells

  1992cites this paper
• Induction of soluble tumour necrosis factor receptors during treatment with interleukin-2.

  1992cites this paper
• Development of immunotherapeutic strategies for the treatment of malignant neoplasms

  1992cites this paper
• Evaluation of toxicity in 22 patients treated with subcutaneous interleukin-2, alpha-interferon with and without chemotherapy.

  1992cites this paper
• Strategies for improving antitumor activity utilizing IL-2: Preclinical models and analysis of antitumor activity of lymphocytes from patients receiving IL-2

  1992cites this paper
• Concomitant administration of recombinant human interleukin-2 and recombinant interferon alfa-2A: an active outpatient regimen in metastatic renal cell carcinoma.

  1992cites this paper
• Tumour necrosis factor mediates the survival benefit of interleukin 2 in a murine pulmonary metastases model.

  1992cites this paper
• Effect of morphine and beta-endorphin on human Fc receptor-dependent and natural killer cell functions.

  1992cites this paper
• Clinical pharmacology of recombinant proteins.

  1992cites this paper
• Effect of human interleukin 3 on the susceptibility of fresh leukemia cells to interleukin-2-induced lymphokine activated killing activity.

  1992cites this paper
• Gamma-irradiated peripheral blood mononuclear cells can express LAK activity.

  1991cites this paper
• Clinical results and characterization of tumor-infiltrating lymphocytes with or without recombinant interleukin 2 in human metastatic renal cell carcinoma.

  1991cites this paper
• Inducibility of lymphokine activated killer (LAK) cells in patients with acute myelogenous leukaemia in complete remission and its clinical relevance

  1991cites this paper
• Antitumor activity, growth, and phenotype of long-term IL-2 cultures of human NK and T lymphocytes.

  1991cites this paper
• Susceptibility of adult acute lymphoblastic leukemia blasts to lysis by lymphokine-activated killer cells.

  1991cites this paper
• [Establishing three dimensional tumors in vitro and the reaction of the lymphokine-activated killer cells (LAK) to the three dimensional tumors].

  1991cites this paper
• Toxicity and reconstitution of recombinant interleukin-2 with albumin.

  1991cites this paper
• Application of Biotechnology Products in Oncology

  1991cites this paper
• Etablierung Dreidimensionaler Tumoren In Vitro und Wirkung von Lymphokinaktivierten Killer (Lak)-Zellen Auf Die Dreidimensionalen Tumoren

  1991cites this paper
• A pilot study of intralymphatic interleukin-2. II. Clinical and biological effects.

  1990cites this paper
• Phase I trial of continuous infusion recombinant interleukin-2 and intermittent recombinant interferon-alpha 2a: clinical effects.

  1990cites this paper
• ヒト肝細胞癌における腫瘍浸潤リンパ球(TIL)の分離増殖と抗腫瘍活性について

  1990cites this paper
• Interleukin 2: Clinical Aspects

  1990cites this paper
• Lymphokine activated killer cells: a new approach to immunotherapy of cancer.

  1990cites this paper
• Splenic versus hepatic artery infusion of interleukin-2 in patients with liver metastases.

  1990cites this paper
• Susceptibility to lysis of pulmonary alveolar macrophages by human lymphokine-activated killer cells.

  1990cites this paper
• Capillary leak syndrome during low dose granulocyte-macrophage colony-stimulating factor (rh GM-CSF) treatment of a patient in a continuous febrile state

  1990cites this paper
• Systemic cancer therapy: four decades of progress and some personal perspectives.

  1990cites this paper
• Phase IB study of low‐dose intraperitoneal recombinant interleukin‐2 in patients with refractory advanced ovarian cancer: Rationale and preliminary report

  1990cites this paper
• A high molecular weight cytotoxic lymphokine in supernatants of lymphokine-activated killer cells cross-reacts with transforming growth factor beta.

  1990cites this paper
• Cellular immune response against autologous human malignant melanoma: are in vitro studies providing a framework for a more effective immunotherapy?

  1990cites this paper
• In vitro lymphocyte response to autologous melanoma: clues in designing new adoptive immunotherapy protocols.

  1989cites this paper
• Culture supernatants of lymphokine-activated killer (LAK) cells contain a high-molecular-weight cytotoxic lymphokine.

  1989cites this paper
• Development of immunotherapeutic strategies for the treatment of malignant neoplasia.

  1989cites this paper
• Inotropic and vasoactive drug treatment of interleukin 2 induced hypotension in sheep.

  1989cites this paper
• Inotropicand VasoactiveDrugTreatmentof Interleukin2 InducedHypotension in Sheep

  1989cites this paper
• Passive immunization against tumor necrosis factor partially abrogates interleukin 2 toxicity

  1989cites this paper
• Phase IB study of low-dose intraperitoneal recombinant interleukin-2 in patients with refractory advanced ovarian cancer: rationale and preliminary report.

  1989cites this paper
• Analysis of effector mechanisms in cancer.

  1989cites this paper